Compass Therapeutics, Inc. (CMPX)
CMPX Stock Price Chart
Explore Compass Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze CMPX price movements and trends.
CMPX Company Profile
Discover essential business fundamentals and corporate details for Compass Therapeutics, Inc. (CMPX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Apr 2021
Employees
35.00
CEO
Thomas J. Schuetz
Description
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
CMPX Financial Timeline
Browse a chronological timeline of Compass Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.14.
Earnings released on 11 Aug 2025
EPS came in at -$0.14 falling short of the estimated -$0.13 by -7.69%.
Earnings released on 8 May 2025
EPS came in at -$0.12 matching the estimated -$0.12.
Earnings released on 27 Feb 2025
EPS came in at -$0.11 falling short of the estimated -$0.10 by -10.00%.
Earnings released on 12 Nov 2024
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 12 Aug 2024
EPS came in at -$0.10 matching the estimated -$0.10, while revenue for the quarter reached $850.00K .
Earnings released on 13 May 2024
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 21 Mar 2024
EPS came in at -$0.11 falling short of the estimated -$0.09 by -22.22%, while revenue for the quarter reached $2.84M .
Earnings released on 9 Nov 2023
EPS came in at -$0.08 surpassing the estimated -$0.11 by +27.27%.
Earnings released on 3 Aug 2023
EPS came in at -$0.09 falling short of the estimated -$0.08 by -12.50%.
Earnings released on 4 May 2023
EPS came in at -$0.06 surpassing the estimated -$0.11 by +45.45%.
Earnings released on 15 Mar 2023
EPS came in at -$0.10 surpassing the estimated -$0.11 by +9.09%.
Earnings released on 9 Nov 2022
EPS came in at -$0.12 falling short of the estimated -$0.11 by -9.09%.
Earnings released on 1 Aug 2022
EPS came in at -$0.08 surpassing the estimated -$0.09 by +11.11%.
Earnings released on 9 May 2022
EPS came in at -$0.07 surpassing the estimated -$0.14 by +50.00%.
Earnings released on 21 Mar 2022
EPS came in at -$0.15 falling short of the estimated -$0.07 by -114.29%.
Earnings released on 12 Nov 2021
EPS came in at -$0.10 surpassing the estimated -$0.12 by +16.67%.
Earnings released on 16 Aug 2021
EPS came in at -$1.07 .
Earnings released on 30 Apr 2021
EPS came in at -$0.14 .
Earnings released on 11 Mar 2021
EPS came in at -$0.15 .
Earnings released on 5 Mar 2021
EPS came in at -$0.14 .
CMPX Stock Performance
Access detailed CMPX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.